CTRI/2019/06/019695尚未招募2 期
PHASE II OPEN, COMPARATIVE NON RANDOMIZED CLINICAL EVALUATION OF VARMAM THERAPY AND SIDDHA DRUG “SIRUPANCHAMOOLA KASAYAM (INTERNAL), THIRUMENI ENNAI (EXTERNAL) IN SAGANAVADAM (CERVICAL SPODYLOSIS) – PATIENTS ATTENDING VARMAM DEPARTMENT OF ANNA HOSPITAL
Government Siddha Medical College1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年6月20日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Outcome of the treatment is assessed by neck disability index, Nurick Classification scoring system, chin test, spurling test, range of movement
研究概览
简要总结
This is an open clinicla study to evaluvate the efficacy of sirupanchamoola kiyazham iInternal trial drug of 100 ml + 1 g Thippilipodi given twice for 6 days and 10 ml external drug applied over the neck and Varmam therapy is given for 60 patients in Anna hospital
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 20.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Complain about dull pain behind the neck in the area of trapezius Radiating pain to the upper limbs Numbness and weakness in arms, hands and fingers Giddiness Muscle spasms in neck and shoulders.
排除标准
- •Trauma Cervical rib Ankylosing spondylosis Cardiac disease Fracture Adhesive capsulitis Caries spine Patient with any other serious systemic illness Malignancy Pregnancy and Lactation.
结局指标
主要结局
Outcome of the treatment is assessed by neck disability index, Nurick Classification scoring system, chin test, spurling test, range of movement
时间窗: 48 Days
次要结局
- Secondary outcome is assessed by comparing the safety parameters before and after treatment(48 Days)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A clinical trial to study the safety and effect of the siddha medicine kattu karunai chooranam in patients having haemorrhoids (Mulai Moolam)CTRI/2020/08/027446Government Siddha Medical College40
Unknown
早期 1 期
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell TransplantationAdult B Acute Lymphoblastic LeukemiaNCT04626726Hebei Senlang Biotechnology Inc., Ltd.50
进行中（未招募）
2 期
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)Ovarian CancerNCT05601752USWM CT, LLC66
尚未招募
2 期
A clinical trial to study the effect of the Siddha medicine in patients having Poly cystic ovarian syndrome (PCOS)CTRI/2020/09/027580Government Siddha Medical college
终止
2 期
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate CancerCastrate-resistant Prostate Cancer (CRPC)NCT03690141Effector Therapeutics16